Pharma BD Deal Intelligence
Genzyme won the Pompe-disease franchise, but not through the technology it paid for
Full analysis, sources & comparables →Genzyme to acquire Novazyme for $137.5M in stock plus up to $87.5M in contingent stock tied to first two product approvals; NZ-1001 was on track to enter…
Crowley became SVP at Genzyme Therapeutics post-close and led the global Pompe program, the largest R&D effort in Genzyme's history at that time, ultimately…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$137.5M Genzyme stock plus up to $87.5M contingent on first two product approvals. Pompe disease ERT (NZ-1001); led to Myozyme. John Crowley/William Canfield platform.
Genzyme won the Pompe-disease franchise, but not through the technology it paid for
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genzyme Corporation / Novazyme Pharmaceuticals Inc. (this deal) | 2001 | $138M | 54 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Genzyme Corporation / Biomatrix Inc. | 2000 | $700M | 65 |
| Genzyme Corporation / Bone Care International, Inc. | 2005 | $600M | 61 |
| Genzyme Corporation / Verigen AG | 2005 | $50M | 29 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
← Browse all deals · How we score deals
More: 2001 deals · Genzyme Corporation deals